EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Everest Medicines's Enterprise Value is HK$5,232.4 Mil.
Everest Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,132.2 Mil. Therefore, Everest Medicines's EV-to-FCF for today is -4.62.
The historical rank and industry rank for Everest Medicines's EV-to-FCF or its related term are showing as below:
HKSE:01952'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.09 Med: -2.84 Max: -1.09
Current: -4.62
During the past 6 years, the highest EV-to-FCF of Everest Medicines was -1.09. The lowest was -6.09. And the median was -2.84.
HKSE:01952's EV-to-FCF is ranked worse than 100% of 369
companies
in the Biotechnology industry
Industry Median: 8.9
vs HKSE:01952: -4.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Everest Medicines's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Everest Medicines's EV-to-FCF
For the Biotechnology subindustry, Everest Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Everest Medicines's EV-to-FCF falls into.
Everest Medicines's current Enterprise Value is HK$5,232.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,132.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Everest Medicines's PE Ratio for today is calculated as:
Everest Medicines's share price for today is HK$22.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.953.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Everest Medicines EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Everest Medicines's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Everest Medicines (HKSE:01952) Business Description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01952 has been successfully added to your 